A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

The University of Virginia is conducting a clinical research study for adults ages 18 to 79, who have Multiple Myeloma. This research study is evaluating whether receiving the study medication with lenalidomide improves disease response in Multiple Myeloma.
If you join this study you will be randomly assigned to either receive lenalidomide alone or both lenalidomide and the study medication along with medications to take before and after the study medication injection.
The actual treatment duration will vary as you will receive the study medication as long as your disease status does not worsen or no other reasons for stopping occur. However, you will receive the study medications for a maximum of 36 cycles. Each cycle is 28 days.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Reimbursement of hotel stay per night per visit; Reimbursement for mileage traveled.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03901963
uvacancertrials@hscmail.mcc.virginia.edu